Search results

Skip to results

Type

Status

Last updated

Showing 1 to 3 of 3 results for somatrogon

  1. Somatrogon for treating growth disturbance in children and young people aged 3 years and over (TA863)

    Evidence-based recommendations on somatrogon (Ngenla) for treating growth disturbance in children and young people aged 3 years and over.

    Technology appraisal guidance
    Published
    1 February 2023
    View recommendations

    Sections for TA863

  2. Somapacitan for treating growth hormone deficiency in people 3 to 17 years (TA1066)

    Evidence-based recommendations on somapacitan (Sogroya) for treating growth hormone deficiency in people 3 to 17 years.

    Technology appraisal guidance
    Published
    3 June 2025
    View recommendations

    Sections for TA1066

  3. NICE recommends a weekly injection for treating growth failure in children

    This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments.

    News
    Last updated
    19 January 2024